Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · IEX Real-Time Price · USD
14.28
-0.45 (-3.05%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Arcus Biosciences Employees
Arcus Biosciences had 577 employees as of December 31, 2023. The number of employees increased by 77 or 15.40% compared to the previous year.
Employees
577
Change (1Y)
77
Growth (1Y)
15.40%
Revenue / Employee
$410,745
Profits / Employee
-$400,347
Market Cap
1.30B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 577 | 77 | 15.40% |
Dec 31, 2022 | 500 | 134 | 36.61% |
Dec 31, 2021 | 366 | 130 | 55.08% |
Dec 31, 2020 | 236 | 97 | 69.78% |
Dec 31, 2019 | 139 | 31 | 28.70% |
Dec 31, 2018 | 108 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Phreesia | 1,438 |
ANI Pharmaceuticals | 642 |
Gyre Therapeutics | 593 |
Immatics | 535 |
Dynavax Technologies | 408 |
Sana Biotechnology | 328 |
Nurix Therapeutics | 284 |
Ardelyx | 267 |
RCUS News
- 12 days ago - Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
- 13 days ago - Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia - Business Wire
- 5 weeks ago - Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers - Business Wire
- 6 weeks ago - Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - Business Wire
- 7 weeks ago - Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer - Business Wire
- 7 weeks ago - Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers - Business Wire
- 2 months ago - Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update - Business Wire
- 2 months ago - Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024 - Business Wire